BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient and mouse studies suggest inhibiting FBXO32 could help treat metastatic breast cancer. In patient tumor samples, FBXO32 expression was higher in invasive tumors than in non-invasive tumors. In a xenograft mouse...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Nov 17, 2017
Preclinical News

FBXO32 regulates mesenchymal transition and promotes metastasis

In a paper published in Nature Communications , researchers at Johannes Gutenberg University and colleagues showed that F-box protein 32 (FBXO32) is necessary for differentiation of adherent epithelial cells into migratory mesenchymal cells, suggesting that targeting...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer F-box protein 11 (FBXO11); snail1 (SNAI1) Mouse and cell culture studies suggest promoting FBXO11-mediated degradation of SNAI1 could help prevent cancer and metastasis. SNAI1...
BioCentury | Sep 12, 2013
Targets & Mechanisms

All in the family

PTEN induced putative kinase 1 is a tantalizing player in familial forms of Parkinson's disease, in which it is inactivated by mutation, but thus far the kinase has been a no-fly zone for drug development...
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Inflammation

...This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation F-box protein 3 (FBXO3)...
BioCentury | Dec 15, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma F-box protein 11 (FBXO11); B cell CLL lymphoma 6 (BCL6) In vitro and mouse studies suggest increasing FBXO11 levels could help treat...
BioCentury | Oct 21, 2010
Targets & Mechanisms

Unnerving atrophy

A team at The University of Texas Southwestern Medical Center at Dallas has shown that deletion of class IIa histone deacetylases prevents muscle atrophy after nerve damage. 1 The result suggests that inhibitors of these...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Autism Astrotactin 2 (ASTN2); constitutive photomorphogenic 1 (RFWD2; COP1); contactin 4 (CNTN4); F-box protein 40 (FBXO40); neuroligin 1 (NLGN1); neurexin 1...
Items per page:
1 - 9 of 9